Ignite Creation Date:
2024-05-06 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05924880
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-25
First Post:
2023-06-01
Brief Title:
A Phase 3b Open-label Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers BTC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Organization Data
Organization:
AstraZeneca
Class:
INDUSTRY
Study ID:
D933AL00006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AstraZeneca
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None